Literature DB >> 9246051

Terbinafine-induced prolonged cholestasis with reduction of interlobular bile ducts.

A Mallat1, E S Zafrani, J M Metreau, D Dhumeaux.   

Abstract

The antifungal drug terbinafine has infrequently been incriminated in the occurrence of acute liver injury. We report a case of prolonged cholestasis that occurred in a 75-year-old woman, following terbinafine administration. Jaundice followed by pruritus appeared after four weeks of therapy and was associated with mixed hepatocellular and cholestatic liver tests abnormalities. Following drug withdrawal, serum bilirubin returned to normal values within three months, but anicteric cholestasis persisted for over six months. A liver biopsy performed after six months showed centrilobular cholestasis, discrete portal fibrosis, and a reduction in the number of interlobular biliary ducts. Terbinafine should be added to the list of drugs that can cause reduction in interlobular bile ducts.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9246051     DOI: 10.1023/a:1018870828038

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  21 in total

1.  Amitriptyline-induced prolonged cholestasis.

Authors:  D Larrey; G Amouyal; D Pessayre; C Degott; O Danne; J P Machayekhi; G Feldmann; J P Benhamou
Journal:  Gastroenterology       Date:  1988-01       Impact factor: 22.682

2.  Hepatitis associated with terbinafine treatment.

Authors:  G Lowe; C Green; P Jennings
Journal:  BMJ       Date:  1993-01-23

3.  Neutropenia and pancytopenia associated with oral terbinafine.

Authors:  M J Kovacs; S Alshammari; L Guenther; M Bourcier
Journal:  J Am Acad Dermatol       Date:  1994-11       Impact factor: 11.527

4.  Stevens-Johnson syndrome after terbinafine therapy.

Authors:  B Rzany; M Mockenhaupt; W Gehring; E Schöpf
Journal:  J Am Acad Dermatol       Date:  1994-03       Impact factor: 11.527

Review 5.  Drug-induced cholestasis.

Authors:  D Larrey; S Erlinger
Journal:  Baillieres Clin Gastroenterol       Date:  1988-04

6.  Terbinafine-induced cholestatic liver disease.

Authors:  G A Lazaros; G V Papatheodoridis; J K Delladetsima; N C Tassopoulos
Journal:  J Hepatol       Date:  1996-06       Impact factor: 25.083

Review 7.  The syndrome of disappearing intrahepatic bile ducts.

Authors:  S Sherlock
Journal:  Lancet       Date:  1987-08-29       Impact factor: 79.321

Review 8.  Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses.

Authors:  J A Balfour; D Faulds
Journal:  Drugs       Date:  1992-02       Impact factor: 9.546

9.  Drug-induced prolonged cholestasis in adults: a histological semiquantitative study demonstrating progressive ductopenia.

Authors:  C Degott; G Feldmann; D Larrey; A M Durand-Schneider; D Grange; J P Machayekhi; A Moreau; F Potet; J P Benhamou
Journal:  Hepatology       Date:  1992-02       Impact factor: 17.425

Review 10.  Clinical pharmacokinetics of terbinafine (Lamisil).

Authors:  J C Jensen
Journal:  Clin Exp Dermatol       Date:  1989-03       Impact factor: 3.470

View more
  10 in total

1.  Prolonged cholestasis with ductopenia after administration of amoxicillin/clavulanic acid.

Authors:  J P Richardet; A Mallat; E S Zafrani; M Blazquez; J C Bognel; B Campillo
Journal:  Dig Dis Sci       Date:  1999-10       Impact factor: 3.199

Review 2.  Systematic review of severe acute liver injury caused by terbinafine.

Authors:  Jun Yan; Xiaolin Wang; Shengli Chen
Journal:  Int J Clin Pharm       Date:  2014-07-02

3.  The role of HLA-A*33:01 in patients with cholestatic hepatitis attributed to terbinafine.

Authors:  Robert John Fontana; Elizabeth Theresa Cirulli; Jiezhun Gu; David Kleiner; David Ostrov; Elizabeth Phillips; Ryan Schutte; Huiman Barnhart; Naga Chalasani; Paul Brent Watkins; Jay H Hoofnagle
Journal:  J Hepatol       Date:  2018-08-21       Impact factor: 25.083

Review 4.  Terbinafine. An update of its use in superficial mycoses.

Authors:  K J McClellan; L R Wiseman; A Markham
Journal:  Drugs       Date:  1999-07       Impact factor: 9.546

5.  N-Acetylcysteine for the Management of Non-Acetaminophen Drug-Induced Liver Injury in Adults: A Systematic Review.

Authors:  Judith Sanabria-Cabrera; Sara Tabbai; Hao Niu; Ismael Alvarez-Alvarez; Anna Licata; Einar Björnsson; Raul J Andrade; M Isabel Lucena
Journal:  Front Pharmacol       Date:  2022-05-17       Impact factor: 5.988

6.  A curious case of cholestasis: oral terbinafine associated with cholestatic jaundice and subsequent erythema nodosum.

Authors:  Kartik Kumar; Anna Gill; Rachelle Shafei; Janine L Wright
Journal:  BMJ Case Rep       Date:  2014-12-05

Review 7.  Practical guidelines for diagnosis and early management of drug-induced liver injury.

Authors:  Kazuto Tajiri; Yukihiro Shimizu
Journal:  World J Gastroenterol       Date:  2008-11-28       Impact factor: 5.742

Review 8.  Terbinafine-induced hepatitis and pancytopenia.

Authors:  G Conjeevaram; V Vongthavaravat; R Sumner; R S Koff
Journal:  Dig Dis Sci       Date:  2001-08       Impact factor: 3.487

Review 9.  Drug-Induced Liver Injury in GI Practice.

Authors:  Naemat Sandhu; Victor Navarro
Journal:  Hepatol Commun       Date:  2020-03-13

10.  Safety and tolerability of oral antifungal agents in the treatment of fungal nail disease: a proven reality.

Authors:  Boni Elewski; Amir Tavakkol
Journal:  Ther Clin Risk Manag       Date:  2005-12       Impact factor: 2.423

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.